AstraZeneca and Trump Administration Announce Historic Deal to Lower U.S. Drug Prices and Boost Domestic Manufacturing

AstraZeneca has announced a landmark agreement with President Donald J. Trump’s administration to significantly reduce prescription medicine costs for American patients while maintaining the nation’s leadership in biopharmaceutical innovation. During an event at the White House, AstraZeneca CEO Pascal Soriot confirmed that the company has voluntarily met all requests outlined in the President’s July 31 letter, committing to align U.S. drug prices with those in other wealthy nations.

Pascal Soriot, Chief Executive Officer, AstraZeneca, said: “Every year AstraZeneca treats millions of Americans living with cancer and chronic diseases and, as a result of today’s agreement, many patients will access life-changing medicines at lower prices. This new approach also helps safeguard America’s pioneering role as a global powerhouse in innovation and developing the next generation of medicines. It is now essential other wealthy countries step up their contribution to fund innovation.”

Under the new framework, AstraZeneca will launch Direct-to-Consumer (DTC) sales through the TrumpRx.gov platform, offering eligible patients with chronic conditions discounts of up to 80% off list prices. Additionally, the company reached an agreement with the U.S. Department of Commerce to defer Section 232 tariffs for three years, enabling the company to fully onshore its U.S. manufacturing. This is part of AstraZeneca’s $50 billion investment plan in U.S.-based manufacturing and R&D over the next five years, targeting $80 billion in total revenue by 2030, half of which is expected to come from the U.S. market.

To support this growth, AstraZeneca has begun construction on its largest manufacturing facility in Virginia, dedicated to its weight management, metabolic, and oncology (ADC) portfolios. The company will also open a newly expanded plant in Coppell, Texas, a cell therapy site in Rockville, Maryland in early 2026, and a new R&D center in Cambridge, Massachusetts by late 2026. With over 25,000 U.S. employees and more than 100,000 supported jobs, AstraZeneca remains deeply committed to expanding its footprint in America, having already contributed approximately $20 billion in economic value in 2025.